A Novel Folic Acid Receptor-Targeted Drug Delivery System Based on Curcumin-Loaded β-Cyclodextrin Nanoparticles for Cancer Treatment
DOI: https://doi.org/10.2147/DDDT.S320119
2021-06-30
Abstract:Weiyong Hong, 1, 2, &ast Fangyuan Guo, 2, &ast Nan Yu, 2 Sanjun Ying, 2 Bang Lou, 2 Jiangqing Wu, 2 Ying Gao, 2 Xugang Ji, 2 Haiying Wang, 1 Aiqin Li, 3 Guoping Wang, 4 Gensheng Yang 2 1 Department of Pharmacy, Taizhou Municipal Hospital, Taizhou, 318000, People's Republic of China; 2 College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China; 3 Zhejiang Share Bio-Pharm Co., Ltd, Hangzhou, 310019, People's Republic of China; 4 Zhejiang Dayang Biotech Group Co., Ltd, Hangzhou, 311616, People's Republic of China &astThese authors contributed equally to this work Correspondence: Gensheng Yang College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China Tel +86571-88871077 Fax +86571-88320913 Email Purpose: A novel folate receptor-targeted β-cyclodextrin (β-CD) drug delivery vehicle was constructed to improve the bioavailability, biosafety, and drug loading capacity of curcumin. Controlled release and targeted delivery was achieved by modifying the nanoparticles with folic acid (FA). Methods: Folate-conjugated β-CD-polycaprolactone block copolymers were synthesized and characterized. Curcumin-loaded nanoparticles (FA-Cur-NPs) were structured by self-assembly. The physicochemical properties, stability, release behavior and tumor-targeting ability of the fabricated nanoparticles were studied. Results: The average particle size and drug loading of FA-Cur-NPs was 151.8 nm and 20.27%, respectively. Moreover, the FA-Cur-NPs exhibited good stability in vitro for 72 h. The drug release profiles showed that curcumin from FA-Cur-NPs was released significantly faster in a pH 6.4 phosphate buffered solution (PBS) than in pH 7.4, indicating that curcumin can be enriched around the tumor site compared with normal cells. Additionally, the internalization of FA-Cur-NPs was aided by FA receptor-mediated endocytosis, and its cytotoxicity was proportional to the cellular uptake efficiency. Furthermore, in vivo studies confirmed that FA-Cur-NPs exhibited marked accumulation in the tumor site and excellent antitumor activity. Conclusion: These findings suggest that FA-Cur-NPs are a promising approach for improving cancer therapy through active targeting and controllable release. Keywords: curcumin, β-CD-polycaprolactone copolymers, folate receptor, targeted drug delivery, HeLa cells Cancer is the most fatal disease threatening human health. According to GLOBOCAN estimates, there were approximately 19.3 million new cases and almost 10.0 million deaths in 2020. 1 Current therapeutic approaches developed for cancer treatment include chemotherapy, immunotherapy, radiation therapy, and surgical excision; 2–4 among them, chemotherapy is the most effective and inexpensive treatment. 5 However, poor targeting selectivity is the main drawback of traditional drugs, which usually cannot distinguish tumors from normal tissues. 6 Therefore, a high dose is administered, resulting in serious adverse effects (eg, side effects and multidrug resistance). 7 Curcumin exhibits a wide range of pharmacological activities such as anti-inflammation, antioxidant, antimicrobial, and anticancer. 8–10 Moreover, the anticancer activity with a high safe dose 11 and ability of multiple cell signaling pathways to regulate different tumors, such as breast, cervical, stomach, liver, and pancreatic cancers as well as colon and epithelial cell carcinomas have received the most attention. 12–15 However, the low water solubility, rapid decomposition, and lack of specific targeting of curcumin under physiological conditions limited its clinical application. 16 To overcome these barriers, nanotechnology has been applied for drug delivery, 17 and active targeted delivery through tumor microenvironment-stimuli responsive systems, such as pH-responsive, 18 , 19 redox-sensitive, 20 and targeting molecule-conjugated nanocarriers, 21 has been employed for tumor diagnosis and treatment. Targeting molecule-conjugated nanocarriers have been widely invest -Abstract Truncated-